Bivalirudin

Identification

Name
Bivalirudin
Accession Number
DB00006 / TN9BEX005G
Groups
Angiomax
Description

Bivalirudin is a artificial 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. once bound to the energetic web page, thrombin can not set off fibrinogen into fibrin, the critical step within the formation of thrombus. it's miles administered intravenously. because it could reason blood stagnation, it is critical to monitor modifications in hematocrit, activated partial thromboplastin time, global normalized ratio and blood strain.

Pharmacology

Pharmacodynamics

Bivalirudin directly and reversibly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin.

Indication

For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.

Action

Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.